ACOBIOM

#pancreaticcancer #epidemiology #cancermanagement #realworlddata #realworldevidence ACOBIOM is pleased to present a real-world study about the epidemiology and management of pancreatic ductal adenocarcinoma (PDAC) in France between 2009 and 2018. The highlights of the study are: > Confirmation of the rising incidence of PDAC mainly among patients > 60 years. > Significant increase of neoadjuvant strategies and chemotherapy delivery. > Improved outcomes in treated patients and modest survival gain overall. Congratulations to the authors: > Léo Mas (AP-HP, Assistance Publique - Hôpitaux de Paris, Hépato-Gastroenterology et Digestive Oncology department, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (APHP), Paris, France), > christel Castelli (AÉSIO Santé, Department Clinical Research team, Institut Mutualiste Montpelliérain - Clinique Beau Soleil, Montpellier, France), > Amandine Coffy (AÉSIO Santé, Department Clinical Research team, Institut Mutualiste Montpelliérain - Clinique Beau Soleil, Montpellier, France), > Brigitte Tretarre (Cancer Herault Network, ICM - Institut du Cancer de Montpellier, France), > David Piquemal (ACOBIOM), > Jean-Baptiste Bachet (AP-HP, Assistance Publique - Hôpitaux de Paris, Hépato-Gastroenterology et Digestive Oncology department, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (APHP), Sorbonne Université, Paris, France). https://lnkd.in/drHRu4EM For more information, please contact the company.

#pancreaticcancer #pancreatic_cancer Panthera DX: a solution for optimizing 1st-line treatments for pancreatic cancer patients. For many years, Acobiom has been developing blood-based diagnostics that help to prescribe the most appropriate therapy for each patient. Panthera DX is a blood-based in-vitro diagnostic capable to predict the patient response to the main first-line therapies used in pancreatic cancer, with the aim to prescribe the most appropriate treatment for patients with metastatic or locally advanced pancreatic cancer. This in-vitro diagnostic will support oncologists and cancer specialists in their decisions by considering: 1. On one hand the health status of pancreatic cancer patients and 2. On the second hand the use of FOLFIRINOX as a superior first-line treatment compared to gemcitabine-based treatments. For more information, please contact Acobiom at busdev [@] acobiom.com https://lnkd.in/drDGX3VX #precisionmedicine #personalizedmedicine #targetedtherapy #targetedtherapies

#pancreaticcancer #pancreatic_cancer Panthera DX is a blood-based in-vitro diagnostic capable to predict the patient response to the main first-line therapies used in pancreatic cancer, with the aim to prescribe the most appropriate treatment for patients with metastatic or locally advanced pancreatic cancer. Panthera DX is based on a predictive RNA signature in peripheral blood for response to FOLFIRINOX or gemcitabine in cases of locally advanced or metastatic pancreatic cancer (see the image below). For more information, please contact Acobiom at busdev [@] acobiom.com #cancer #oncology #oncologists #oncologist #personalizedmedicine #precisionmedicine

#scRNAseq #RNAseq Single-cell DNA or RNA sequencing is emerging as a game-changer in the world of genomics, by providing unprecedented insights into the complexity of cellular behavior within a cell group, organ or tissue. Establishing scRNA-seq profiles requires a succession of technological steps, and above all the use of dedicated bioinformatics and mathematical tools to generate and sort the unique data obtained. For more information: https://lnkd.in/dFfdQD9Q

Cancer du pancréas : pourquoi ça augmente ? par la SNFGE, Société Nationale Française de Gastro-Entérologie #cancerpancreas #cancerdupancreas #pancreaticcancer https://lnkd.in/gTj2bJYy

ACOBIOM is pleased to announce the signature of a partnership agreement with the Montpellier Cancer Institute as part of the GABRINOX-2 a clinical trial in pancreatic cancer. The aim of this partnership is to confirm the predictive value of two company's PCR tests, Gemcitest and Folfitest, blood-based diagnostics predictive of patient response to the main first-line therapies, gemcitabine and FOLFIRINOX, in the treatment of pancreatic cancer. ICM - Institut du Cancer de Montpellier Fabienne Portales Marc Ychou David Piquemal Aurore Moussion

6 mars 2024. Retrouvez David Piquemal à la Conférence "RDV ingénieurs : imaginons le futur" sur le thème : "Quel rôle pour le numérique et la robotique dans les sciences de la vie ?" #sciencesdelavie #numerique #robotique #lifesciences #digital Inscription sur le site : https://lnkd.in/dg9yh8iN

#pancreaticcancer and innate #immunity interact or are linked at different levels: > Inflammation and Tumor Microenvironment > Immune Surveillance > Tumor-Associated Macrophages (TAMs) > Natural Killer (NK) Cells > Cytokines and Chemokines > Dysfunctional Immune Response > Immunosuppression To find out more: https://lnkd.in/d9YD34gU

Pancreatic Cancer: A disease with few therapeutic options Molecular #biomarkers (and #diagnostics) are capable to predict #patient response to a particular drug regimen. Acobiom develops predictive blood-based diagnostics for patient response to the main first-line therapies available. For more information about #pancreaticcancer : https://lnkd.in/dp7y369

ACOBIOM is very pleased to share the JGO Editorial, written by Dr Orla M. Fitzpatrick (Trinity St. James’s Cancer Institute, Dublin, Ireland) and Dr Grainne O'Kane MB, BCH, BAO, MRCPI, MD (Trinity St. James’s Cancer Institute, Dublin, Ireland ; Princess Margaret Cancer Centre, Toronto, Canada): "Determinants of gemcitabine response in pancreatic cancer: are we there?" https://lnkd.in/d6JRD_Zh This conclusion of the editorial is a great recognition of the works performed by the scientific team of the company to target treatments in #pancreaticcancer and to better use #gemcitabine in clinics: "Novel therapeutics in PDAC are desperately needed, Piquemal et al. (JGO 2023) have provided a potential new tool (#Gemcitest) to identify patients with advanced PDAC to predict outcomes with gemcitabine-based protocols and its validation is eagerly awaited."